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DOI 10.1016/j.stem.2012.02.001Recent discussions in this journal have
identified the research need for donated
eggs, concern for the welfare of the
donor, and the ongoing ethical debate
about financial compensation (Hyun,
2011; Egli et al., 2011). It is generally
acknowledged that there needs to be
robust regulatory oversight that takes
into account the physical risks incurred
by the donor. In response to these issues,
we initiated an egg-sharing scheme for
women undergoing IVF treatment. Review
of the outcome for these women indicates
that this source of eggs has proved to
be successful for both patients and
researchers.
An ‘‘egg sharer’’ is a woman who
donates half of the eggs collected during
her IVF procedure in return for a reduced
treatment cost. Egg sharing for treatment
provides eggs so that another woman
may have a child and is an established
practice in the UK (HFEA, 2006, 2011).
Egg sharing for research (ESR) should in
principle be a less ethically challenging
option because no child results from the
procedure. Nonetheless, there are still
concerns expressed about ‘‘exploitation’’
and ‘‘commodification’’ that are compli-
cated by the context of embryo research
and financial transactions. The Nuffield
Council on Bioethics recently published
a report addressing the ethical issues
surrounding donation of bodily tissue to
medicine and research that included
gamete donation and financial compen-
sation (Nuffield Council for Bioethics,
2011). Notwithstanding the ethical issues
surrounding ESR, their qualified recom-
mendation states, ‘‘We do not think it
appropriate to recommend any changes
to the current policy within the UK of
permitting egg-sharing’’ (Summary 53).
The focus of this letter is not to revisit
the ethical discussions surrounding this
issue, but instead to supplement them
with practical information about imple-
mentation of an egg-sharing scheme.The process of obtaining regulatory
approval for our scheme in the UK was
robust. The Research Ethics Committee
approved our proposal in December
2005. HFEA deliberations from December
2005 included discussion at two Authority
meetings, their License Committee, their
Ethics Committee, a public consultation,
and a legal appeal to the License
Committee before final approval in
September 2006. The subsequent fund-
ing by the MRC permitted ESR and
recruitment starting in late 2007.
Women viewed as being suitable
donors were <36 years old with a good
ovarian reserve (FSH < 10 IU/l, and
a good response to previous superovula-
tion or antral follicle count >12) and met
a requirement for self-funded IVF treat-
ment. The ovarian stimulation protocol
was our standard IVF regime. ESR
reduced the cost of IVF treatment by
£1,500 (unreduced cost: £3,200–£3,700).
Written information was given about the
research, and consent for ESR was ob-
tained by an independent research nurse
(see the Supplemental Information for a
copy of the information provided and the
consent form).
Between 2008 and 2010, 265 women
requested information about the scheme.
One-hundred and twelve met the criteria
and fifty-nine agreed to participate. Seven
women withdrew consent at egg collec-
tion and ten had an unexpectedly poor
response to superovulation and so re-
tained all their eggs for their IVF treatment
at the reduced cost. Thus 42 women
completed 51 ESR treatments (5 had 2
and 2 had 3 ESR treatments). ESR re-
sulted in 467 fresh oocytes being donated
to research and being utilized for ap-
proved research projects.
One criticism of ESR is that it reduces
the chance of pregnancy to the donor,
and thus may require her to have more
treatment to achieve the same pregnancy
rate. To evaluate this possibility we iden-Cell Stem Celltified 51 contemporaneous matched
patients from nonsharers who had
comparable demographic and clinical
characteristics (selected to reflect param-
eters known to influence IVF outcome),
i.e., age, cause of infertility, previous
pregnancy, treatment type (IVF/ICSI),
number of previous treatments, and
number of oocytes collected (Templeton
andMorris, 1998). Thus, repeat ESR treat-
ments were matched with new controls to
take an account of the additional previous
treatment.
The mean numbers (±SD) of follicles
aspirated (20.3 ± 10.5 versus 18.8 ±
8.82) and oocytes obtained (15.2 ± 9.21
versus 14.6 ± 7.01) in each group were
similar. The mean number of metaphase
II eggs in each group was 8.38 ± 4.7
versus 12.9 ± 6.5. The number of embryos
was 5.08 ± 3.34 (range: 1–14 embryos;
median: 5) generated in the ESR group,
compared to 8.46 ± 4.92 in the control
group (range: 1–25 embryos; median: 8,
p < 0.0001). Ten women had embryos
cryopreserved in the nonsharing control
group (19.6%) but none of the ESR
women did (p < 0.01). No women devel-
oped complications or were hospitalized.
The positive pregnancy test and live
birth rate per treatment started (LBR)
were 41.1% and 37.25% for ESR group
and 47.1% and 29.4% for the control
group (NSp>0.2). Themultiple pregnancy
LBR was comparable between both
groups at 21.05% (n = 4) versus 20%
(n = 3). Of the 10 control women with
frozen embryos, 2 women still have them
stored, 2 have discarded them, and 6
women had frozen embryo transfer result-
ing in one birth. Thus the cumulative LBR
for nonshared paired control group was
31.3%.
UK data demonstrates that neither the
presence of >15 eggs (Sunkara et al.,
2011) nor the presence of >4 embryos
improves LBR (Templeton and Morris,
1998). Thus, such women (young with a10, March 2, 2012 ª2012 Elsevier Inc. 239
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Letter‘‘good prognosis’’) do not need all the
eggs that they produce after superovula-
tion to achieve optimum LBR. Selection
of such patients for ESR therefore seems
feasible and they should still achieve
better than average LBR. The physical
risk to the donor is the same as standard
IVF treatment.
In addition, the patient experience in
our scheme was analyzed in an MRC-
funded independent study in which all
ESR patients were invited to focused
interviews. One area of analysis was the
potential for exploitation, and the overall
conclusion was that ‘‘most grounds for
acknowledging the potential of the ESR
to be exploitative are dismissed and other
grounds are cited for rejecting the charge
outright’’ (Haimes et al., 2012).
Because egg availability remains a
significant rate-limiting factor for research
progress, we would argue that all options
should be considered. We agree with the240 Cell Stem Cell 10, March 2, 2012 ª2012view that nonpatient egg donors must not
be discriminated against in comparison
to participants in other medical research
by being denied appropriate financial
compensation for their time, effort, and
inconvenience (Hyun, 2011). Nonetheless,
we offer the egg sharing option that we
investigated as a practical and ethically
acceptable alternative to egg donation
solely dedicated to research.SUPPLEMENTAL INFORMATION
Supplemental Information for this article includes
the information provided to donors and the
consent form and can be found with this article on-
line at doi:10.1016/j.stem.2012.02.001.
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